Resources / Development of a Spatial Metabolic Map of Immunotherapy Sensitive and Resistant Cutaneous Skin Carcinoma
Phenoplex™
Development of a Spatial Metabolic Map of Immunotherapy Sensitive and Resistant Cutaneous Skin Carcinoma
Originally presented at AACR 2023
Background

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and represents a major global health burden. Approximately 50% of cSCC patients develop primary resistance and 20% will develop secondary resistance to immune checkpoint inhibitors (ICI). There are limited biomarkers that reflect the tumor dynamics predictive of response to ICI therapy, and therefore we need to explore new biomarkers that can better understand the cSCC tumor microenvironment (TME).

Authors and institutions

Niyati Jhaveri1, Dmytro Klymyshyn1, Bassem B. Cheikh1, James Monkman2, Dan Winkowski3, James Mansfield3, Subham Basu4, Michael Prater4, Nadine Nelson4, Gabrielle Belz2, Oliver Braubach1, Arutha Kulasinghe2

  1. Akoya Biosciences, Menlo Park, CA
  2. The University of Queensland, Brisbane, Australia
  3. Visiopharm A/S, Horsholm, Denmark
  4. Abcam, Cambridge, United Kingdom
Questions? We’re here to help.
Contact us
Success
Your message has been successfully sent!